

# Sun Pharma, AZPIL tie up to sell Axcer

## Heart disease treatment drug to be available in India

PRESS TRUST OF INDIA

New Delhi


DRUG majors Sun Pharmaceutical and AstraZeneca Pharma India on Tuesday said they have entered into a distribution services agreement to distribute AstraZeneca's heart disease treatment drug 'Axcer' in India.

"AZPIL and Sun Pharma have entered into a distribution services agreement in India for AstraZeneca's brand 'Axcer', a new brand of ticagrelor," Sun Pharma said in a BSE filing.

The company added that AZPIL already has a brand 'Brilinta' for ticagrelor molecule in India since 2012. Axcer is a drug that is used for the treatment of acute coronary syndrome (ACS).

Sun Pharma India Business CEO Abhay Gandhi said: "Such collaborations are also part of our stated policy of becoming the partner of choice for promotion and distribution of innovative pharmaceutical products in the country."

Sanjay Murdeshwar,



### Together for life

■ Sun Pharma said that AZPIL already has a brand 'Brilinta' for ticagrelor molecule in India since 2012. Axcer is a drug used for the treatment of acute coronary syndrome (ACS)

MD, AstraZeneca Pharma India, said: "Ticagrelor works by preventing the formation of new blood clots and maintains blood flow in the body, helping reduce a patient's risk of another heart attack or cardiovascular-related death."

The company further

said: "This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby, benefiting a greater number of ACS patients. It strengthens Sun Pharma's cardiology portfolio with the addition of a new patented therapy."

Industry